# Exscientia Plc (EXAI)

Source: https://www.quantisnow.com/company/EXAI
Generated: 2026-11-11T11:39:20.740Z

- Ticker: EXAI
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2021
- Website: https://www.exscientia.ai

## About

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.

## Latest EXAI news and filings

- 2024-12-02 13:39 UTC [SEC Form 15-12G filed by Exscientia Plc](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-exscientia-plc-5795375)
- 2024-11-23 02:11 UTC [SEC Schedule 13G] [Amendment: SEC Form SC 13G/A filed by Exscientia Plc](https://www.quantisnow.com/insight/amendment-sec-form-sc-13ga-filed-by-exscientia-plc-5789230)
- 2024-11-23 01:00 UTC [SEC Schedule 13D] [Amendment: SEC Form SC 13D/A filed by Exscientia Plc](https://www.quantisnow.com/insight/amendment-sec-form-sc-13da-filed-by-exscientia-plc-5789196)
- 2024-11-20 15:01 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Exscientia Plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-exscientia-plc-5784596)
- 2024-11-20 14:53 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Exscientia Plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-exscientia-plc-5784580)
- 2024-11-20 14:20 UTC [SEC Form 6-K] [SEC Form 6-K filed by Exscientia Plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-exscientia-plc-5784565)
- 2024-11-20 14:03 UTC [SEC Form 25-NSE filed by Exscientia Plc](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-exscientia-plc-5784546)
- 2024-11-20 12:00 UTC [Conference Announcement] [Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery](https://www.quantisnow.com/insight/recursion-and-exscientia-two-leaders-in-the-ai-drug-discovery-5784184)
- 2024-11-13 15:37 UTC [SEC Form 6-K] [SEC Form 6-K filed by Exscientia Plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-exscientia-plc-5770565)
- 2024-11-13 14:08 UTC [Recursion and Exscientia Shareholders Approve the Proposed Combination](https://www.quantisnow.com/insight/recursion-and-exscientia-shareholders-approve-the-proposed-combination-5770383)
- 2024-11-12 21:55 UTC [SEC Form 6-K] [SEC Form 6-K filed by Exscientia Plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-exscientia-plc-5768667)
- 2024-11-08 11:40 UTC [SEC Form 6-K] [SEC Form 6-K filed by Exscientia Plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-exscientia-plc-5760799)
- 2024-11-06 11:08 UTC [SEC Form 6-K] [SEC Form 6-K filed by Exscientia Plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-exscientia-plc-5754377)
- 2024-10-16 11:00 UTC [Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration](https://www.quantisnow.com/insight/exscientia-achieves-milestones-for-two-programmes-in-sanofi-collaboration-5726522)
- 2024-10-10 10:04 UTC [SEC Form 6-K] [SEC Form 6-K filed by Exscientia Plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-exscientia-plc-5721609)
- 2024-10-09 11:00 UTC [Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024](https://www.quantisnow.com/insight/exscientia-to-present-new-preclinical-data-for-ai-designed-lsd1-and-5720403)
- 2024-09-30 12:00 UTC [Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting](https://www.quantisnow.com/insight/data-demonstrating-enpp1-inhibition-as-a-therapeutic-approach-for-later-onset-5707857)
- 2024-08-30 12:57 UTC [SEC Form 6-K] [Amendment: SEC Form 6-K/A filed by Exscientia Plc](https://www.quantisnow.com/insight/amendment-sec-form-6-ka-filed-by-exscientia-plc-5677451)
- 2024-08-28 20:42 UTC [SEC Form 6-K] [SEC Form 6-K filed by Exscientia Plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-exscientia-plc-5675148)
- 2024-08-28 11:00 UTC [Conference Announcement] [Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference](https://www.quantisnow.com/insight/exscientia-to-present-at-the-morgan-stanley-22nd-annual-global-5674165)
- 2024-08-15 11:19 UTC [SEC Form 6-K] [SEC Form 6-K filed by Exscientia Plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-exscientia-plc-5660570)
- 2024-08-15 11:00 UTC [Exscientia Business Update for Second Quarter and First Half 2024](https://www.quantisnow.com/insight/exscientia-business-update-for-second-quarter-and-first-half-2024-5660519)
- 2024-08-08 21:19 UTC [SEC Form 6-K] [SEC Form 6-K filed by Exscientia Plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-exscientia-plc-5651567)
- 2024-08-08 11:39 UTC [Leadership Update] [Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities](https://www.quantisnow.com/insight/recursion-and-exscientia-enter-definitive-agreement-to-create-a-global-5649263)
- 2024-08-06 10:42 UTC [Latest Updates of Viva Biotech's Portfolio Companies](https://www.quantisnow.com/insight/latest-updates-of-viva-biotechs-portfolio-companies-5643570)
- 2024-07-18 11:24 UTC [SEC Form 6-K] [SEC Form 6-K filed by Exscientia Plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-exscientia-plc-5614461)
- 2024-07-18 11:04 UTC [Market Chatter] [Exscientia Agrees To Acquire GT Apeiron's Share Of Its Oral CDK7 Inhibitor Program, Gaining Full Control Of GTAEXS617 And All Related Intellectual Property; To Pay GT Apeiron $10M Upfront Cash](https://www.quantisnow.com/insight/exscientia-agrees-to-acquire-gt-apeirons-share-of-its-oral-5614423)
- 2024-07-18 11:00 UTC [Mergers & Acquisitions] [Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout](https://www.quantisnow.com/insight/exscientia-acquires-full-rights-to-potential-best-in-class-cdk7-inhibitor-ahead-5614398)
- 2024-07-10 11:18 UTC [Market Chatter] [Exscientia Will Expand Its Work With Amazon Web Services Using The Cloud Provider's Artificial Intelligence And Machine Learning Services To Power Its Platform For End-To-End Drug Discovery And Automation](https://www.quantisnow.com/insight/exscientia-will-expand-its-work-with-amazon-web-services-using-5600806)
- 2024-07-10 11:00 UTC [Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery](https://www.quantisnow.com/insight/exscientia-launches-aws-ai-powered-platform-to-advance-drug-discovery-5600761)
- 2024-07-09 11:31 UTC [Analyst Coverage Initiated] [TD Cowen initiated coverage on Exscientia plc](https://www.quantisnow.com/insight/td-cowen-initiated-coverage-on-exscientia-plc-5598540)
- 2024-07-09 10:59 UTC [Market Chatter] [TD Cowen Initiates Coverage On Exscientia with Buy Rating](https://www.quantisnow.com/insight/td-cowen-initiates-coverage-on-exscientia-with-buy-rating-5598376)
- 2024-06-06 20:12 UTC [SEC Form 6-K] [SEC Form 6-K filed by Exscientia Plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-exscientia-plc-5542522)
- 2024-06-06 11:00 UTC [Leadership Update] [Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology](https://www.quantisnow.com/insight/exscientia-appoints-new-leaders-to-strengthen-the-impact-of-integrated-5540890)
- 2024-05-30 11:00 UTC [Conference Announcement] [Exscientia to Present at Upcoming Investor Conferences in June](https://www.quantisnow.com/insight/exscientia-to-present-at-upcoming-investor-conferences-in-june-5524558)
- 2024-05-23 20:07 UTC [SEC Form 6-K] [SEC Form 6-K filed by Exscientia Plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-exscientia-plc-5513610)
- 2024-05-21 15:38 UTC [Market Chatter] [Exscientia shares are trading lower after the company reported worse-than-expected Q1 sales results.](https://www.quantisnow.com/insight/exscientia-shares-are-trading-lower-after-the-company-reported-worse-than-expected-5506777)
- 2024-05-21 11:50 UTC [SEC Form 6-K] [SEC Form 6-K filed by Exscientia Plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-exscientia-plc-5505921)
- 2024-05-21 11:06 UTC [Market Chatter] [Exscientia's Cash, Cash Equivalents And Short-term Bank Deposits As Of March 31, 2024 Were $416.9M, Which Is Expected To Provide Cash Runway Into 2027](https://www.quantisnow.com/insight/exscientias-cash-cash-equivalents-and-short-term-bank-deposits-as-of-5505779)
- 2024-05-21 11:03 UTC [Market Chatter] [Exscientia Q1 2024 GAAP EPS $(0.21) Beats $(0.39) Estimate, Sales $6.700M Miss $7.509M Estimate](https://www.quantisnow.com/insight/exscientia-q1-2024-gaap-eps-021-beats-039-estimate-sales-5505768)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/EXAI
- Earnings history: https://www.quantisnow.com/earnings/EXAI
- Dividend history: https://www.quantisnow.com/dividends/EXAI
- Insider transactions: https://www.quantisnow.com/insiders/EXAI
- Options chain: https://www.quantisnow.com/options/EXAI
- SEC 8-K filings only: https://www.quantisnow.com/company/EXAI/8-k
- RSS and alerts for EXAI: https://www.quantisnow.com/docs/rss-feeds.md